Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy”.
-
Clinical Benefit
| Substantial |
The actual benefit of PLAVIX in this new indication is substantial. |
Clinical Added Value
| moderate |
The Transparency Committee considers that in this new indication, PLAVIX provides a moderate improvement in actual benefit (IAB III) for patient management. |
Contact Us
Évaluation des médicaments
